Last reviewed · How we verify

NCT04604340

Radial Versus Femoral Arterial Access for Cerebral Angiography in Adolescents

Terminated NA Last updated 28 October 2021
What this trial tests

NA trial testing transradial access for neuroangiography in Procedural Related Injuries and Complications Nec in 12 participants. Terminated before completion.

Timeline
22 September 2020
Primary endpoint
1 June 2021
1 June 2021

Quick facts

Lead sponsorThe Hospital for Sick Children
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeother
Enrollment12
Start date22 September 2020
Primary completion1 June 2021
Estimated completion1 June 2021
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

The Hospital for Sick Children

Who can join

Adults 8 to 18, any sex, with Procedural Related Injuries and Complications Nec or Patient Satisfaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will compare radial vs femoral access for angiography in adolescents. Neuroangiography and neurointerventions are predominantly performed via femoral access, which has several limitations and complications - pain and discomfort, arterial occlusion, retroperitoneal hemorrhage, activity limitations, and increased admissions. Transradial angiography has shown promise to circumvent these problems, but this has not been studied in children, whose unique anatomical and physiological aspects require that this be evaluated rigorously.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other The Hospital for Sick Children trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04604340.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing